Need professional-grade analysis? Visit stockanalysis.com
$453.83M
N/A
N/A
N/A
Price Chart
Risk-Adjusted Performance
Immix Biopharma Inc (IMMX) Price Performance
Immix Biopharma Inc (IMMX) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $8.57, down 5.93% from the previous close.
Over the past year, IMMX has traded between a low of $1.36 and a high of $10.46. The stock has gained 368.3% over this period. It is currently 18.1% below its 52-week high.
Immix Biopharma Inc has a market capitalization of $453.83M.
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Company Info
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- N/A
- EBITDA
- $-23,836,024
- Profit Margin
- N/A
- EPS (TTM)
- -0.77
- Book Value
- 0.25
Technical Indicators
- 52 Week High
- $11.23
- 52 Week Low
- $1.34
- 50 Day MA
- $6.77
- 200 Day MA
- $4.01
- Beta
- 0.26
Valuation
- Trailing P/E
- N/A
- Forward P/E
- -14.97
- Price/Sales
- N/A
- Price/Book
- 34.28
- Enterprise Value
- $272.92M